A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration

Clinical Ophthalmology

Volumn 7, Issue , 2013, Pages 1987-1993

  Kitchens, John W ^a   Kassem, Nawal ^b   Wood, William ^a   Stone, Thomas W ^a   Isernhagen, Rick ^a   Wood, Edward ^a   Hancock, Brad A ^b   Radovich, Milan ^b   Waymire, Josh ^b   Li, Lang ^b   Schneider, Bryan P ^b  

^a Retina Associates of Kentucky   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Age related macular degeneration; ARMS2; Bevacizumab; Complement factor H (CFH); LOC387715; Ranibizumab; Single nucleotide polymorphisms; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; COMPLEMENT FACTOR H; RANIBIZUMAB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

AGED; ARTICLE; COMPLEMENT FACTOR H GENE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; LOC387715 GENE; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; PHARMACOGENETICS; PREDICTIVE VALUE; RETINA MACULA AGE RELATED DEGENERATION; SINGLE NUCLEOTIDE POLYMORPHISM; VASCULAR ENDOTHELIAL GROWTH FACTOR GENE; VISUAL ACUITY;

EID: 84885448955     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S39635     Document Type: Article

References (19)

1. Friedman DS, O'Colmain BJ, Munoz B, etal. The Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122(4):564-572.
2. Brown DM, Kaiser PK, Michels M, etal. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432-1444.
3. Rosenfeld PJ, Brown DM, Heier JS, etal. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. October 5, 2006;355(14):1419-1431.
4. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MaA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113(3):363-372.
5. Chiang A, Regillo CD. Preferred therapies for neovascular age-related macular degeneration. Curr Opin Ophthalmol. 2011;22(3):199-204.
6. Schneider BP, Wang M, Radovich M, etal. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol. 2008;26(28):4672-4678.
7. Seddon JM, Francis PJ, George S, Schultz DW, Rosner B, Klein ML. Association of CFH Y402H and LOC387715A69S with progression of age-related macular degeneration. JAMA. 2007;297(16):1793-1800.
8. Rivera A, Fisher SA, Fritsche LG, etal. Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum Mol Genet. 2005;14(21):3227-3236.
9. Brantley MA Jr, Fang AM, King JM, Tewari A, Kymes SM, Shiels A. Association of complement factor H and LOC387715genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology. 2007;114(12):2168-2173.
10. Imai D, Mori K, Horie-Inoue K, etal. CFH, VEGF, and PEDF genotypes and the response to intravitreous injection of bevacizumab for the treatment of age-related macular degeneration. J Oc Biol DisInfor. 2010;3(2):53-59.
11. Lee AY, Raya AK, Kymes SM, Shiels A, Brantley MA. Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab. Bri J Ophthalmol. 2009;93(5): 610-613.
12. Boltz A, Ruibeta M, Jonas JB, etal. Role of vascular endothelial growth factor polymorphisms in the treatment success in patients with wet age-related macular degeneration. Ophthalmology. 2012;119(8): 1615-1620.
13. Shuler RK Jr, Hauser MA, Caldwell J, etal. Neovascular age-related macular degeneration and its association with LOC387715 and complement factor H polymorphism. Arch Ophthalmol. 2007;125(1):63-67.
14. Teper SJ, Nowinska A, Pilat J, Palucha A, Wylegala E. Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration. Mol Vis. 2010;16: 2598-2604.
15. Chakravarthy U, Harding SP, Rogers CA, etal. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119(7):1399-1411.
16. Martin DF, Maguire MG, Fine SL, etal. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388-1398.
17. Sakurada Y, Kubota T, Imasawa M, Mabuchi F, Tanabe N, Iijima H. Association of LOC387715A69S genotype with visual prognosis after photodynamic therapy for polypoidal choroidal vasculopathy. Retina. 2010;30(10):1616-1621.
18. Bessho H, Honda S, Kondo N, Negi A. The association of age-related maculopathy susceptibility 2 polymorphisms with phenotype in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Mol Vis. 2011;17:977-982.
19. Park DH, Kim IT. LOC387715/HTRA1 variants and the response to combined photodynamic therapy with intravitreal bevacizumab for polypoidal choroidal vasculopathy. Retina. 2012;32(2):299-307.